Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM) of the pharma sector has released the results for the third quarter of the business year 2024.
After the results today, many brokerage firms have released reports on this stock. After the results, these brokerage firms have predicted further rise in the stock.
During the October-December quarter, the company saw good growth in its Indian, German, and Brazilian businesses.
Talking about the results, the company’s profit has increased by almost 57% in the third quarter.
Due to strong demand from the domestic market and better performance of Germany and Brazil business, the company’s profit has increased to ₹ 443 crore as compared to ₹ 283 crore in the same quarter a year ago.
Income also increased by 9.7% on an annual basis to ₹2732 crore.
Sales in the Indian business have increased by 12% and sales in the Brazilian business have increased by 26%.
Talking about EBITDA margin, it has also seen an improvement of 270 basis points, after which it has reached 31.8%.
Let us know further what is the commentary of brokerage firms on this stock after the results and what is the target they are seeing in it.
One global brokerage firm has set a target of Rs 2790, another Brokerage gave buy rating and set target of around 2860, and third one has set a target of Rs 3650 for this share.
About Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited is an India-based pharmaceutical firm.
The company focuses on different therapeutic segments including cardiovascular (CV) and central nervous system (CNS), digestive (GI) Vitamins minerals nutrition (VMN) & anti-diabetes (AD), the gynecology field, pain, and dermatology.
The company is involved in the research development, manufacturing marketing, and distribution of brand & generic formulations of pharmaceuticals both in India and across the world.
The brands used for its children’s products are Tedibar, Atogla, Spoo, and B4 Nappi. The acne/facecare brands it sells comprise Clinmiskin, ACNEMOIST, TRACNILO, and FASH.
The company’s hair and scalp care are sold under the brands Proanagen, Perlice, Permite, and NOSKURF.
The manufacturing facilities are located within the States of Gujarat, Madhya Pradesh, Himachal Pradesh, Andhra Pradesh, and Sikkim.
The main channel for distribution is via wholesale drug distributors, the largest stockists retailers, and pharmacies.
Fundamental Analysis of Torrent Pharmaceuticals Ltd
| Market Cap | ₹ 89,508 Cr. |
| Current Price | ₹ 2,638 |
| 52-wk High | ₹ 2,685 |
| 52-wk Low | ₹1,446 |
| Stock P/E | 62.5 |
| Book Value | ₹ 198 |
| Dividend | 0.83 % |
| ROCE | 19.8 % |
| ROE | 20.0 % |
| Face Value | ₹ 5.00 |
| P/B Value | 13.3 |
| OPM | 30.7 % |
| EPS | ₹ 44.1 |
| Debt | ₹ 4,487 Cr. |
| Debt to Equity | 0.67 |
Torrent Pharmaceuticals Share Price Target 2024 To 2030
| Year | 1st Target | 2nd Target |
| 2024 | ₹2700 | ₹3650 |
| 2025 | ₹3700 | ₹3765 |
| 2026 | ₹3800 | ₹3990 |
| 2027 | ₹4000 | ₹4235 |
| 2028 | ₹4300 | ₹4459 |
| 2029 | ₹4500 | ₹4687 |
| 2030 | ₹4700 | ₹4798 |
Torrent Pharmaceuticals Ltd Shareholding Pattern
| Promoters Holding | |
| Dec 2022 | 71.25% |
| Mar 2023 | 71.25% |
| June 2023 | 71.25% |
| Sept 2023 | 71.25% |
| Dec 2023 | 71.25% |
| FII Holding | |
| Dec 2022 | 12.09% |
| Mar 2023 | 12.04% |
| June 2023 | 12.85% |
| Sept 2023 | 13.15% |
| Dec 2023 | 14.08% |
| DII Holding | |
| Dec 2022 | 8.77% |
| Mar 2023 | 8.89% |
| June 2023 | 8.22% |
| Sept 2023 | 7.91% |
| Dec 2023 | 7.11% |
| Govt. Holding | |
| Dec 2022 | 0.10% |
| Mar 2023 | 0.10% |
| June 2023 | 0.10% |
| Sept 2023 | 0.10% |
| Dec 2023 | 0.10% |
| Public Holding | |
| Dec 2022 | 7.78% |
| Mar 2023 | 7.71% |
| June 2023 | 7.59% |
| Sept 2023 | 7.59% |
| Dec 2023 | 7.46% |
Torrent Pharmaceuticals Ltd Share: Last 5 Years’ Financial Condition
To gain a better understanding of how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹7,673 Cr |
| 2020 | ₹7,939 Cr |
| 2021 | ₹8,005 Cr |
| 2022 | ₹8,508 Cr |
| 2023 | ₹10,474 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹436 Cr |
| 2020 | ₹1,025 Cr |
| 2021 | ₹1,252 Cr |
| 2022 | ₹777 Cr |
| 2023 | ₹1,494 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 1.03 |
| 2020 | 0.91 |
| 2021 | 0.83 |
| 2022 | 0.67 |
| 2023 | 0.85 |
Last 10 Years’ Profit Growth:
| 10 Years: | 10% |
| 5 Years: | 14% |
| 3 Years: | 7% |
| Current Year: | 15% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | 24% |
| 5 Years: | 19% |
| 3 Years: | 20% |
| Last Year: | 20% |
Sales Growth Over 10 Years:
| 10 Years: | 12% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| Current Year: | 13% |
Conclusion
This article is a complete guide about Torrent Pharmaceuticals Ltd Share.
These information and forecasts are based on our analysis, research, company fundamentals and history, experiences, and various technical analyses.
Also, We have talked in detail about the share’s future prospects and growth potential.
Hopefully, these informations will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
If you have any further queries, please comment below. We will be happy to answer all your questions.
If you like this information, share the article with as many people as possible.
Also Read: 72% Govt Holding Railway Share Giving Excellent Return; Again Huge Order Received
